FcRn: IgG or HSA Inhibitor Screening Chemiluminescent Assay Kit

The FcRn: IgG or HSA Inhibitor Screening Chemiluminescent Assay Kit is designed for screening and profiling biologics targeting the interaction between human FcRn (Neonatal Fc receptor for IgG) and Human Serum Albumin (HSA) or between human FcRn and human Fc (IgG1), respectively. This kit comes in a convenient 96-well format, with enough Fc (IgG1) (amino acids 100-330), Biotinylated HSA and His-tagged FcRn (FCGRT/B2M) (amino acids 24-297 of FCGRT and 21-119 of B2M), as well as anti-His detection antibody, Streptavidin-HRP, and assay buffers for 100 reactions.Figure.1 Assay principleThis universal assay kit provides flexibility as it allows to choose between two protocols for profiling biologics targeting the Fc (IgG1) :FcRn or FcRn:HSA interactions, respectively.Protocol A:Fc (IgG1) is coated on a 96-well plate overnight. The plate is incubated with an inhibitor or neutralizing antibody together with FcRn, washed, and treated with anti-His detection antibody to assess the fraction of His-tagged FcRn bound to the Fc (IgG1) . Addition of an HRP-conjugated substrate produces chemiluminescence, which is proportional to the amount of FcRn bound to Fc (IgG1) .Protocol B:Fc (IgG1) is coated on a 96-well plate overnight. FcRn is added and captured by the coated Fc (IgG1) . Next, the plate is incubated with an inhibitor or neutralizing antibody together with biotinylated HSA. Finally, the plate is washed and treated with Streptavidin-HRP, followed by addition of an HRP substrate to produce chemiluminescence. The chemiluminescence signal is proportional to the binding of HSA to FcRn.Interested in having us perform the screening and profiling of inhibitors or blocking antibodies? Visit our ImmunotherapyBiochemical Screening Services.